Views

CrossRef citations to date

Altmetric

Original Research

Gender differences in the association between C-reactive protein, lung function impairment, and COPD

Inga Sif Ólafsdóttir1 Department of Medical Sciences: Respiratory Medicine and Allergology, Uppsala University, Uppsala, SwedenCorrespondence[email protected]

Thórarinn Gíslason2 Department of Allergy, Respiratory Medicine and Sleep, Landspitali University Hospital, Reykjavik, Iceland

Bjarni Thjóđleifsson3 Department of Gastroenterology, Landspitali University Hospital, Reykjavik, Iceland

Ísleifur Ólafsson4 Department of Clinical Biochemistry, Landspitali University Hospital, Reykjavik, Iceland

Davíd Gíslason2 Department of Allergy, Respiratory Medicine and Sleep, Landspitali University Hospital, Reykjavik, Iceland

Rain Jõgi5 Lung Clinic of Tartu University Hospital, Tartu, Estonia

Christer Janson1 Department of Medical Sciences: Respiratory Medicine and Allergology, Uppsala University, Uppsala, Sweden

show all

Figures & data

Table 1 Characteristics of the study population in relation to CRP values

Download CSV Display Table

Figure 1 Correlation between pack years and CRP in ex- and current smokers.

Table 2 Prevalence of GOLD stage 0 and COPD and the independent association to CRP

Download CSV Display Table

Figure 2 Correlation between CRP values and FEV₁ expressed as % of the predicted in subjects with COPD (n = 53).

Figure 2 Correlation between CRP values and FEV1 expressed as % of the predicted in subjects with COPD (n = 53).

Table 3 Estimated effect (95% CI) of CRP on lung function. Subjects with CRP value ≤ 0.45 mg/L are the reference group. The values are adjusted for centre, age, (age)², height, BMI and pack years (estimate in mL (95% CI))

Download CSV Display Table

Table 4 Estimated effect (95% CI) of CRP on annual decline in FEV₁ (mL/year). Subjects with CRP value ≤ 0.45 mg/L are the reference group. The values are adjusted for centre, age, (age)², height, BMI at baseline, change in BMI and pack years

Download CSV Display Table

Figure 3 Estimated difference in FEV₁ (A) and FVC (B) between subjects with different CRP values, where subjects in the 1st CRP quartile are the reference. The estimates are adjusted for age, sex, BMI and pack years.

Figure 3 Estimated difference in FEV1 (A) and FVC (B) between subjects with different CRP values, where subjects in the 1st CRP quartile are the reference. The estimates are adjusted for age, sex, BMI and pack years.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Gender differences in the association between C-reactive protein, lung function impairment, and COPD

Table 1 Characteristics of the study population in relation to CRP values

Table 2 Prevalence of GOLD stage 0 and COPD and the independent association to CRP

Table 3 Estimated effect (95% CI) of CRP on lung function. Subjects with CRP value ≤ 0.45 mg/L are the reference group. The values are adjusted for centre, age, (age)², height, BMI and pack years (estimate in mL (95% CI))

Table 4 Estimated effect (95% CI) of CRP on annual decline in FEV₁ (mL/year). Subjects with CRP value ≤ 0.45 mg/L are the reference group. The values are adjusted for centre, age, (age)², height, BMI at baseline, change in BMI and pack years

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Gender differences in the association between C-reactive protein, lung function impairment, and COPD

Figures & data

Table 1 Characteristics of the study population in relation to CRP values

Table 2 Prevalence of GOLD stage 0 and COPD and the independent association to CRP

Table 3 Estimated effect (95% CI) of CRP on lung function. Subjects with CRP value ≤ 0.45 mg/L are the reference group. The values are adjusted for centre, age, (age)2, height, BMI and pack years (estimate in mL (95% CI))

Table 4 Estimated effect (95% CI) of CRP on annual decline in FEV1 (mL/year). Subjects with CRP value ≤ 0.45 mg/L are the reference group. The values are adjusted for centre, age, (age)2, height, BMI at baseline, change in BMI and pack years

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Table 3 Estimated effect (95% CI) of CRP on lung function. Subjects with CRP value ≤ 0.45 mg/L are the reference group. The values are adjusted for centre, age, (age)², height, BMI and pack years (estimate in mL (95% CI))

Table 4 Estimated effect (95% CI) of CRP on annual decline in FEV₁ (mL/year). Subjects with CRP value ≤ 0.45 mg/L are the reference group. The values are adjusted for centre, age, (age)², height, BMI at baseline, change in BMI and pack years